Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure

Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol

(2018) Marie-Eve Muller et al.   ADVANCES IN THERAPY

Incidence of Hospitalisation for Heart Failure and Case-Fatality Among 3.25 Million People with and without Diabetes

(2018) David A. McAllister et al.   CIRCULATION

Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology

(2018) Petar M. Seferović et al.   EUROPEAN JOURNAL OF HEART FAILURE

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure

(2018) Kevin Damman et al.   JACC-Heart Failure

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

(2017) David Fitchett et al.   EUROPEAN HEART JOURNAL

The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors

(2017) Javed Butler et al.   EUROPEAN JOURNAL OF HEART FAILURE

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial

(2017) David Z I Cherney et al.   Lancet Diabetes & Endocrinology

The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition

(2017) Subodh Verma et al.   JAMA Cardiology

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

(2017) Christoph Wanner et al.   CIRCULATION

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

(2016) Sunder Mudaliar et al.   DIABETES CARE

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

(2016) David Fitchett et al.   EUROPEAN HEART JOURNAL

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN JOURNAL OF HEART FAILURE

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

(2014) Bernard Zinman et al.   Cardiovascular Diabetology

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

(2014) Marko Škrtić et al.   DIABETOLOGIA

The Global Health and Economic Burden of Hospitalizations for Heart Failure

(2014) Andrew P. Ambrosy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

(2013) T. Heise et al.   DIABETES OBESITY & METABOLISM

Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey

(2013) Vincent M. van Deursen et al.   EUROPEAN JOURNAL OF HEART FAILURE